Welcome to BrainStorm Cell Therapeutics
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Cell Therapeutics to Report Fourth Quarter and Full Year 2014 Financial Results on Thursday, March 26
Hackensack, NJ and Petach Tikvah, Israel – March 19, 2015 – BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report fourth quarter and full year 2014 financial results on Thursday, March 26, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the financial results and answer questions. Read More...
Click here for our Company Presentation at the Stem Cell on the Mesa meeting in San Diego, October 2013.
Click here for a summary of the data presented at the American Academy of Neurology meeting, March 2013.